Thaum Lub Kaum Ib Hlis 4, 2021, Merck/Ridgeback tshaj tawm tias British Tshuaj thiab Cov Khoom Siv Khomob Tswjhwm Saib Xyuas Kev Noj Qab Haus Huv (MHRA) tau pom zoo kev lag luam ntawm molnupiravir (MK-4482, EIDD-2801) hauv UK rau kev kho mob ntawm cov neeg laus cov neeg mob me me mus rau nruab nrab. COVID19. Molnupiravir yog lub ntiaj teb' thawj qhov tshuaj tiv thaiv kab mob hauv qhov ncauj tau pom zoo rau kev kho mob me me mus rau nruab nrab COVID-19 rau cov neeg laus. Cov neeg mob no tau kuaj pom zoo rau SARS-CoV-2 thiab muaj tsawg kawg yog ib qho kev pheej hmoo rau kev tsim kab mob hnyav.
Molnupiravir (MK-4482/EIDD-2801) yog ib qho nucleoside analog nrhiav tau los ntawm DRIVE (Drug Innovations ntawm Emory), lub koom haum tsis muaj txiaj ntsig koom nrog Emory University, nws cov haujlwm los tiv thaiv SARS-CoV-2 replication yog 3-10 npaug siab dua. tshaj li ntawm Remdesivir, thiab tau qhia txog kev ua haujlwm hauv ntau tus kab mob preclinical SARS-CoV-2 tiv thaiv kab mob, kho thiab tiv thaiv qauv.
Lub Rau Hli 9 xyoo no, Merck tau kos npe rau daim ntawv cog lus nrog rau tsoomfwv Meskas. Thaum nws tau txais kev tso cai siv thaum muaj xwm txheej ceev lossis kev pom zoo los ntawm FDA, nws yuav muab US tsoom fwv nrog 1.7 lab chav kawm ntawm molnupiravir. Merck kuj tau kos npe rau kev yuav khoom thiab muab cov ntawv cog lus rau molnupiravir nrog rau lwm lub tseem fwv thoob ntiaj teb, thiab tam sim no tab tom sib txuas lus nrog tsoomfwv ntau dua.
Tau qhov twg los: Official AccountMedicine Cube Plus
